Carmen Pérez Casas

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Alexandra Calmy, Tamara Tovar-Sanchez, Charles Kouanfack et al. · The Lancet HIV · 2020 · 164 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Clinicoepidemiological Study of Imported Malaria in Travelers and Immigrants to Madrid

Rogelio López‐Vélez, Antônio Brazil Viana, Carmen Pérez Casas et al. · Journal of Travel Medicine · 1999 · 42 citations

Veterinary Medicine, Health Sciences, Infectious Diseases +17

Dengue in Spanish travelers returning from the tropics

Rogelio López‐Vélez, Carmen Pérez Casas, A. Vance Vorndam et al. · European Journal of Clinical Microbiology & Infectious Diseases · 1996 · 41 citations

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +12

Pricing of drugs and donations: options for sustainable equity pricing

Carmen Pérez Casas, Emilia Herranz, Nathan Ford · Tropical Medicine & International Health · 2001 · 38 citations

Pharmacy, Pharmaceutical Policy, Global Health +16

Cutting the cost of South African antiretroviral therapy using newer, safer drugs

François Venter, Bonnie N. Kaiser, Yogan Pillay et al. · South African Medical Journal · 2016 · 36 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17